DE602005009852D1 - Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration - Google Patents

Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration

Info

Publication number
DE602005009852D1
DE602005009852D1 DE602005009852T DE602005009852T DE602005009852D1 DE 602005009852 D1 DE602005009852 D1 DE 602005009852D1 DE 602005009852 T DE602005009852 T DE 602005009852T DE 602005009852 T DE602005009852 T DE 602005009852T DE 602005009852 D1 DE602005009852 D1 DE 602005009852D1
Authority
DE
Germany
Prior art keywords
cell migration
cannabidiol
tumor cell
brain tumor
inhibit brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005009852T
Other languages
English (en)
Inventor
Brian Whittle
Daniela Parolaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of DE602005009852D1 publication Critical patent/DE602005009852D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE602005009852T 2004-10-01 2005-09-30 Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration Active DE602005009852D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0421900A GB2418612A (en) 2004-10-01 2004-10-01 Inhibition of tumour cell migration with cannabinoids
PCT/GB2005/003793 WO2006037981A1 (en) 2004-10-01 2005-09-30 Inhibition of tumour cell migration

Publications (1)

Publication Number Publication Date
DE602005009852D1 true DE602005009852D1 (de) 2008-10-30

Family

ID=33427951

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005009852T Active DE602005009852D1 (de) 2004-10-01 2005-09-30 Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration

Country Status (10)

Country Link
US (3) US20080262099A1 (de)
EP (1) EP1802274B1 (de)
JP (5) JP2008514687A (de)
AT (1) ATE408412T1 (de)
CA (1) CA2582289C (de)
DE (1) DE602005009852D1 (de)
DK (1) DK1802274T3 (de)
ES (1) ES2313414T3 (de)
GB (1) GB2418612A (de)
WO (1) WO2006037981A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
WO2008144475A1 (en) * 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2460672B (en) * 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
GB2478074B (en) * 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
KR20120111125A (ko) * 2011-03-31 2012-10-10 주식회사한국전통의학연구소 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
AU2014223458A1 (en) 2013-02-28 2015-10-15 Full Spectrum Laboratories Limited Biosynthesis of cannabinoids
GB2516814B (en) * 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
US9394510B2 (en) 2014-08-25 2016-07-19 Full Spectrum Laboratories Limited Apparatus and methods for the simultaneous production of compounds
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
EP3250200A4 (de) 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Verfahren zur herstellung von cannabisölextrakten und zusammensetzungen
US20180074045A1 (en) * 2015-05-27 2018-03-15 Cannabics Pharmaceuticals Inc System and method for high throughput screening of cancer cells
WO2017091764A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
KR20190034576A (ko) 2016-08-03 2019-04-02 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
WO2021055079A1 (en) 2019-09-16 2021-03-25 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2164584A1 (es) * 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
US6448288B1 (en) * 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
EP1361864B9 (de) * 2001-02-14 2014-07-09 GW Pharma Limited Flüssige spray formulierungen zur buccalen verabreichung von cannabinoiden
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products

Also Published As

Publication number Publication date
CA2582289C (en) 2014-10-14
ES2313414T3 (es) 2009-03-01
CA2582289A1 (en) 2006-04-13
GB0421900D0 (en) 2004-11-03
JP2017031190A (ja) 2017-02-09
US20190255011A1 (en) 2019-08-22
GB2418612A (en) 2006-04-05
WO2006037981A8 (en) 2006-06-01
JP2015038137A (ja) 2015-02-26
DK1802274T3 (da) 2009-02-02
EP1802274B1 (de) 2008-09-17
JP6280489B2 (ja) 2018-02-14
EP1802274A1 (de) 2007-07-04
US20120225136A1 (en) 2012-09-06
JP2014094960A (ja) 2014-05-22
JP2012131803A (ja) 2012-07-12
JP2008514687A (ja) 2008-05-08
ATE408412T1 (de) 2008-10-15
WO2006037981A1 (en) 2006-04-13
US20080262099A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
ATE408412T1 (de) Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration
NL301145I2 (nl) Tirbanibulin
DK1809280T3 (da) Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
EA200802213A1 (ru) Способы лечения заболеваний крови
CY1109551T1 (el) Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
ATE408601T1 (de) Fredericamycin-derivate
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
BR112015002357A2 (pt) compostos e composições ativadores de enzimas
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE410235T1 (de) Behandlung von ballastwasser
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
EA200601471A1 (ru) Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты)
MX2009011388A (es) Inhibidores de polimerasa y su uso para el tratamiento de tumores.
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
ATE536181T1 (de) Metabolite von wortmannin-analogen und verwendungsverfahren dafür
BRPI0510503A (pt) compostos e composições como inibidores de catepsina s

Legal Events

Date Code Title Description
8364 No opposition during term of opposition